Cumberland Partners Ltd Acquires 19,130 Shares of AbbVie Inc. $ABBV

Cumberland Partners Ltd increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 76.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 44,232 shares of the company’s stock after acquiring an additional 19,130 shares during the period. Cumberland Partners Ltd’s holdings in AbbVie were worth $10,241,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Evolution Wealth Management Inc. bought a new stake in AbbVie in the second quarter valued at $26,000. Spurstone Advisory Services LLC bought a new position in shares of AbbVie during the second quarter valued at $28,000. Financial Gravity Companies Inc. acquired a new stake in shares of AbbVie in the 2nd quarter valued at $36,000. Delos Wealth Advisors LLC bought a new stake in shares of AbbVie in the 2nd quarter worth about $39,000. Finally, Redmont Wealth Advisors LLC bought a new stake in shares of AbbVie in the 3rd quarter worth about $41,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

NYSE:ABBV opened at $228.79 on Thursday. The company has a market cap of $404.36 billion, a price-to-earnings ratio of 96.95, a P/E/G ratio of 0.81 and a beta of 0.35. The stock’s fifty day moving average price is $224.01 and its two-hundred day moving average price is $221.68. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the previous year, the company posted $2.16 earnings per share. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of recent analyst reports. Piper Sandler boosted their price target on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday. HSBC raised AbbVie from a “hold” rating to a “buy” rating and boosted their target price for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 price target on shares of AbbVie in a report on Wednesday, January 28th. JPMorgan Chase & Co. lifted their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Finally, Citigroup decreased their target price on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $251.56.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.